Key facts
- Somagenetix’s last known valuation is $16.3M (Aug 2025).
- It has raised $16.4M; the latest was Later Stage VC ($2.5M) in Aug 2025.
- Notable investors include Verve Ventures, Zürcher Kantonalbank, Schroders Capital, Vi Partners, University of Zürich — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Somagenetix
- ·The full record, as it builds
Funding rounds
No funding rounds for Somagenetix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Somagenetix
Operator of a biotechnology company intended to develop new cell and gene therapies to treat patients with severe inherited immune diseases. The company focuses on the discovery and development of stem cells from bone marrow and on the delivery of therapeutic genes via lentiviral vectors to compensate for inborn genetic defects, and on the transplantation of gene-corrected cells back into patients, enabling doctors to correct the underlying genetic cause of disease and cure patients with various monogenetic defects.
- Sector
- Healthcare
- HQ
- Altendorf, Switzerland
- Founded
- 2018
- Employees
- 10
- Website
- somagenetix.com/
- Ownership
- Privately Held (backing)
Somagenetix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Somagenetix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Somagenetix in its N-PORT filings yet. We sweep new filings monthly.